Log in to save to my catalogue

Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody...

Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_315551fc1cbd4c92a2cda7a6a3e401c0

Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement

About this item

Full title

Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement

Publisher

England: BioMed Central

Journal title

Italian journal of pediatrics, 2022-01, Vol.48 (1), p.7-7, Article 7

Language

English

Formats

Publication information

Publisher

England: BioMed Central

More information

Scope and Contents

Contents

The fast diffusion of the SARS-CoV-2 pandemic have called for an equally rapid evolution of the therapeutic options.
The Human recombinant monoclonal antibodies (mAbs) have recently been approved by the Food and Drug Administration (FDA) and by the Italian Medicines Agency (AIFA) in subjects aged ≥12 with SARS-CoV-2 infection and specific risk f...

Alternative Titles

Full title

Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_315551fc1cbd4c92a2cda7a6a3e401c0

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_315551fc1cbd4c92a2cda7a6a3e401c0

Other Identifiers

ISSN

1824-7288,1720-8424

E-ISSN

1824-7288

DOI

10.1186/s13052-021-01187-1

How to access this item